Bioatla Stock Performance
| BCAB Stock | USD 1.57 0.18 12.95% |
The firm shows a Beta (market volatility) of 1.36, which signifies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Bioatla will likely underperform. At this point, Bioatla has a negative expected return of -0.11%. Please make sure to confirm Bioatla's total risk alpha, skewness, rate of daily change, as well as the relationship between the maximum drawdown and accumulation distribution , to decide if Bioatla performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Bioatla has generated negative risk-adjusted returns adding no value to investors with long positions. Despite latest weak performance, the Stock's basic indicators remain strong and the current disturbance on Wall Street may also be a sign of long term gains for the company investors. ...more
1 | Disposition of 572 shares by Sievers Eric of Bioatla at 1.77 subject to Rule 16b-3 | 08/30/2024 |
2 | BioAtla Announces Upcoming Poster Presentation at the 2024 European Society for Medical Oncology Annual Meeting | 09/09/2024 |
3 | BioAtla out-licenses BA3362 to Context Therapeutics | 09/23/2024 |
4 | Michael Burry just bought 633,959 shares in this 1 penny stock - MSN | 09/30/2024 |
5 | Michael Burry is now up 65 percent in just 3 months on this Chinese stock | 10/02/2024 |
6 | BioAtla Announces Upcoming Poster Presentation at the th Society for Immunotherapy of Cancer Annual Meeting | 10/04/2024 |
7 | BioAtla GAAP EPS of -0.22 beats by 0.15, revenue of 11M | 11/07/2024 |
8 | BioAtla, Inc. Q3 2024 Earnings Call Transcript | 11/11/2024 |
9 | BioAtlas SWOT analysis oncology biotech stock faces pivotal year | 11/21/2024 |
| Begin Period Cash Flow | 215.5 M |
Bioatla |
Bioatla Relative Risk vs. Return Landscape
If you would invest 187.00 in Bioatla on August 24, 2024 and sell it today you would lose (30.00) from holding Bioatla or give up 16.04% of portfolio value over 90 days. Bioatla is currently does not generate positive expected returns and assumes 5.8743% risk (volatility on return distribution) over the 90 days horizon. In different words, 52% of stocks are less volatile than Bioatla, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Bioatla Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Bioatla's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Bioatla, and traders can use it to determine the average amount a Bioatla's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0182
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | BCAB |
Estimated Market Risk
| 5.87 actual daily | 52 52% of assets are less volatile |
Expected Return
| -0.11 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.02 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Bioatla is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Bioatla by adding Bioatla to a well-diversified portfolio.
Bioatla Fundamentals Growth
Bioatla Stock prices reflect investors' perceptions of the future prospects and financial health of Bioatla, and Bioatla fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Bioatla Stock performance.
| Return On Equity | -1.39 | ||||
| Return On Asset | -0.5 | ||||
| Operating Margin | (1.02) % | ||||
| Current Valuation | 10.68 M | ||||
| Shares Outstanding | 48.35 M | ||||
| Price To Book | 2.93 X | ||||
| Price To Sales | 6.11 X | ||||
| Gross Profit | (79.35 M) | ||||
| EBITDA | (122.24 M) | ||||
| Net Income | (123.46 M) | ||||
| Cash And Equivalents | 178.12 M | ||||
| Cash Per Share | 4.77 X | ||||
| Total Debt | 2.46 M | ||||
| Debt To Equity | 0.03 % | ||||
| Current Ratio | 7.48 X | ||||
| Book Value Per Share | 0.47 X | ||||
| Cash Flow From Operations | (104.02 M) | ||||
| Earnings Per Share | (1.70) X | ||||
| Market Capitalization | 67.2 M | ||||
| Total Asset | 119.66 M | ||||
| Retained Earnings | (416.26 M) | ||||
| Working Capital | 88.06 M | ||||
About Bioatla Performance
By analyzing Bioatla's fundamental ratios, stakeholders can gain valuable insights into Bioatla's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Bioatla has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Bioatla has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (1.03) | (1.08) | |
| Return On Capital Employed | (1.42) | (1.35) | |
| Return On Assets | (1.03) | (1.08) | |
| Return On Equity | (1.75) | (1.66) |
Things to note about Bioatla performance evaluation
Checking the ongoing alerts about Bioatla for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Bioatla help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Bioatla generated a negative expected return over the last 90 days | |
| Bioatla has high historical volatility and very poor performance | |
| Bioatla may become a speculative penny stock | |
| Net Loss for the year was (123.46 M) with loss before overhead, payroll, taxes, and interest of (79.35 M). | |
| Bioatla currently holds about 178.12 M in cash with (104.02 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.77, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Latest headline from investing.com: BioAtlas SWOT analysis oncology biotech stock faces pivotal year |
- Analyzing Bioatla's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Bioatla's stock is overvalued or undervalued compared to its peers.
- Examining Bioatla's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Bioatla's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Bioatla's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Bioatla's stock. These opinions can provide insight into Bioatla's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Bioatla Stock analysis
When running Bioatla's price analysis, check to measure Bioatla's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Bioatla is operating at the current time. Most of Bioatla's value examination focuses on studying past and present price action to predict the probability of Bioatla's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Bioatla's price. Additionally, you may evaluate how the addition of Bioatla to your portfolios can decrease your overall portfolio volatility.
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing |